Orforglipron
Oral GLP-1 receptor agonist · Also known as LY3502970, OWL833
What is Orforglipron?
An oral non-peptide GLP-1 receptor agonist being developed by Eli Lilly. It could become the first pill-form alternative to injectable GLP-1 drugs like semaglutide.
Orforglipron is a small molecule that activates the GLP-1 receptor without being a peptide itself. This means it can be taken as a daily pill rather than requiring injection. Phase 2 trials showed up to 14.7% body weight loss over 36 weeks.
Benefits & evidence
How it works
Unlike peptide-based GLP-1 agonists (semaglutide, tirzepatide), orforglipron is a small molecule that activates the GLP-1 receptor through a different binding mechanism. Because it's not a peptide, it resists degradation in the digestive tract and can be absorbed orally.
Once absorbed, it works the same way as injectable GLP-1 agonists: suppressing appetite, slowing gastric emptying, and improving insulin sensitivity. The daily pill format could dramatically improve adherence compared to weekly injections.
Dosing information
Typical dosing protocol
3-12 mg/day
Titration period12-36 mg/day
OngoingPhase 3 trials are ongoing. Dosing may change based on final trial results.
Side effects
Most side effects tend to improve as your body adjusts.